Latest News

Latest News

Designing Resilient Health Systems That Endure

Designing Resilient Health Systems That Endure

The most resilient health systems are not the ones that respond best in times of disruption, they’re the ones designed so that when disruption occurs, care continues and communities remain protected. Systems continue to struggle with workforce shortages, delayed care,...

read more
Weekly News Roundup | 21 September 2026

Weekly News Roundup | 21 September 2026

Life science news 21 September 2026: first US Sanfilippo approval, DESTINY-Lung04 data and a NICE OCD consultation. The FDA approved Fayuvi, the first treatment for Sanfilippo syndrome type A. AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of lung cancer...

read more
Azetukalner NDA Filed as Xenon Pauses Depression Trials

Azetukalner NDA Filed as Xenon Pauses Depression Trials

Xenon Pharmaceuticals submitted the azetukalner NDA to the US Food and Drug Administration on 17 September 2026. The filing covers focal seizures in epilepsy. The same announcement disclosed a voluntary pause on new enrolment in the company’s depression studies. Xenon...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

The Gut Microbiome and the Future of Human Health

The Gut Microbiome and the Future of Human Health

The gut microbiome has moved from a niche area of research to one of the most important frontiers in modern medicine. Once associated mainly with digestion, it is now understood to be a complex, organ-like system that influences immunity, metabolism and even brain...

read more
Clinical Trials Roundup | 10 April 2026

Clinical Trials Roundup | 10 April 2026

Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...

read more
The FDA PMTA Roundtable: Initial Reflections

The FDA PMTA Roundtable: Initial Reflections

Product characterisation remains the critical test of submission strength The US Food and Drug Administration (FDA) convened a roundtable on the Premarket Tobacco Product Application (PMTA) process, bringing together discussions on product characterisation,...

read more
Closing the Interventional Gap

Closing the Interventional Gap

The National Health Service (NHS) is investing heavily in diagnostics. Through Getting it Right First Time (GIRFT) and the rollout of Community Diagnostic Centres (CDCs), millions of patients are getting scans more quickly than ever[1]. The NHS 10 Year Plan has now...

read more
Weekly News Roundup | 6 April 2026

Weekly News Roundup | 6 April 2026

Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...

read more
Natural Diamonds in Healthcare

Natural Diamonds in Healthcare

When we say "diamonds," most people think of a luxurious necklace or a super sparkly ring. A research lab would be the last place people imagine them being used. Interestingly, natural diamonds are getting a lot of attention in science and healthcare research. And...

read more
Clinical Trials Roundup | 03 April 2026

Clinical Trials Roundup | 03 April 2026

Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...

read more
Erectile Dysfunction is Preventable – if You Act Early

Erectile Dysfunction is Preventable – if You Act Early

Did you know that your erections can tell you more about your heart health than you might think? Nocturnal erections—those spontaneous erections that happen during sleep—are directly tied to vascular health. When a man stops having them, even for a short period of...

read more
The Gut Microbiome and the Future of Human Health

The Gut Microbiome and the Future of Human Health

The gut microbiome has moved from a niche area of research to one of the most important frontiers in modern medicine. Once associated mainly with digestion, it is now understood to be a complex, organ-like system that influences immunity, metabolism and even brain...

read more
Clinical Trials Roundup | 10 April 2026

Clinical Trials Roundup | 10 April 2026

Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...

read more
The FDA PMTA Roundtable: Initial Reflections

The FDA PMTA Roundtable: Initial Reflections

Product characterisation remains the critical test of submission strength The US Food and Drug Administration (FDA) convened a roundtable on the Premarket Tobacco Product Application (PMTA) process, bringing together discussions on product characterisation,...

read more
Closing the Interventional Gap

Closing the Interventional Gap

The National Health Service (NHS) is investing heavily in diagnostics. Through Getting it Right First Time (GIRFT) and the rollout of Community Diagnostic Centres (CDCs), millions of patients are getting scans more quickly than ever[1]. The NHS 10 Year Plan has now...

read more
Weekly News Roundup | 6 April 2026

Weekly News Roundup | 6 April 2026

Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...

read more
Natural Diamonds in Healthcare

Natural Diamonds in Healthcare

When we say "diamonds," most people think of a luxurious necklace or a super sparkly ring. A research lab would be the last place people imagine them being used. Interestingly, natural diamonds are getting a lot of attention in science and healthcare research. And...

read more
Clinical Trials Roundup | 03 April 2026

Clinical Trials Roundup | 03 April 2026

Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...

read more
Erectile Dysfunction is Preventable – if You Act Early

Erectile Dysfunction is Preventable – if You Act Early

Did you know that your erections can tell you more about your heart health than you might think? Nocturnal erections—those spontaneous erections that happen during sleep—are directly tied to vascular health. When a man stops having them, even for a short period of...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Rethinking Commercial Strategy for Late Biopharma Entrants

Rethinking Commercial Strategy for Late Biopharma Entrants

Being first to market in a new therapeutic class is often seen as a winning formula in biopharma. In reality, many of the biggest commercial successes come second, or even later. The difference is not luck. It is timing, differentiation and scale. Understanding late...

read more
Python Blood Molecule Opens Door to New Obesity Treatments

Python Blood Molecule Opens Door to New Obesity Treatments

Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...

read more
Weekly News Roundup | 30 March 2026

Weekly News Roundup | 30 March 2026

Life science news 30 March 2026: Three blockbuster deals, two FDA accelerated approvals and intensifying GLP-1 competition headline a busy week for pharma and biotech. Merck agreed on 25 March to acquire Terns Pharmaceuticals for $6.7 billion, gaining access to...

read more
Clinical Trials Roundup | 27 March 2026

Clinical Trials Roundup | 27 March 2026

An RNA therapy that preserves muscle while cutting visceral fat, a first in class oral non incretin obesity pill, late stage lung cancer portfolio data, NK cell immunotherapy in Alzheimer’s disease, and the first human trial of a cellular rejuvenation medicine...

read more
New Report Highlights Why CGTs Still Struggle at Market Access

New Report Highlights Why CGTs Still Struggle at Market Access

Cell and gene therapies are approved — so why aren’t they reaching patients? New industry report warns access systems — not science — are now the primary bottleneck A new report from Phacilitate argues that the biggest threat to cell and gene therapy (CGT) expansion...

read more
The Radical Longevity Science Frontier

The Radical Longevity Science Frontier

For decades, longevity has been a frontier of scientific exploration, pushing the boundaries of what we believe is possible for human health and lifespan. While incremental progress has been made in understanding the biology of aging, we are now on the cusp of a new...

read more
Key Thoughts from the on! PLUS TPL Review

Key Thoughts from the on! PLUS TPL Review

The evolving PMTA landscape for nicotine pouches The recent FDA authorisation of on! PLUS nicotine pouches is a significant moment in helping meet tobacco harm reduction (THR) goals. They are the first products to pass a new, faster FDA programme, signifying a...

read more
From Flower to Pharmacy: The Science Behind Manuka Honey

From Flower to Pharmacy: The Science Behind Manuka Honey

Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...

read more
Weekly News Roundup | 23 March 2026

Weekly News Roundup | 23 March 2026

Your essential life science news  23 March 2026 digest: the past week’s biggest stories in pharma, biotech and healthcare. The FDA approved Johnson and Johnson's once-daily psoriasis pill ICOTYDE (icotrokinra) on 18 March, making it the world's first oral peptide to...

read more

Further News

LSD Anxiety Data: Definium Hits All Phase 3 Endpoints

Definium Therapeutics has reported positive results from its first Phase 3 LSD anxiety trial. The data push a psychedelic medicine closer to a regulatory filing in a condition that has not seen a new drug approval since 2007. The company said on 12 August that Voyage...

Panthera Opens New Clinical Research Clinic at Keele University

13 August 2026 - Panthera has opened its latest clinical trial clinic at Keele University, further strengthening its growing clinical research network across the UK and Europe. Panthera, which is the UK's largest independent Site Management Organisation (SMO),...

Clinical Trials Roundup | 14 Aug 2026

Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...

From Laboratory to Market: Risk Planning for Life Science Companies

The UK life sciences sector is entering an important phase of growth. The Government's Life Sciences Sector Plan sets an ambition for the UK to become the leading life sciences economy in Europe by 2030 and the third globally by 2035. It also reports that the sector...

Biopharma VC Funding in H1 2026: Megarounds Mask an Early-Stage Squeeze

Biopharma VC funding delivered its strongest opening half in four years. Yet the headline figure hides a widening split. Mature, de-risked companies are attracting capital, while the seed-stage startups that supply the sector’s long-term pipeline are not. Data...

Organ Digital Twins: Inside Imperial College London’s Research

Organ digital twins have moved from mathematical curiosity to funded national priority. Imperial College London now sits close to the centre of that shift. Researchers there have built more than 3,800 anatomically accurate virtual hearts. They have also begun an NHS...

Glass Slides to AI: Digital Pathology Can Transform Cancer Care in the NHS

Every year, millions of pathology slides are produced in the UK, most still examined manually under a microscope. This century-old process, though reliable, is no longer fit for purpose. Pathology departments face mounting workforce pressures, with 78% pathologists...

Kidney Care’s $2.5 Billion Timing Problem

Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...

Blood Supplies Set For Vital Boost as Donation Rules Are Updated

Long-running campaign removes unnecessary barrier for blood donors, a victory for both patients and the blood donation service* Patients receiving acupuncture from appropriately qualified practitioners will no longer have to wait four months before donating blood,...

In Vivo CAR-T Therapy: The Next Frontier in Cell Therapy Explained

In vivo CAR-T therapy has travelled from laboratory concept to clinical reality faster than almost any modality in recent memory. Conventional cell therapy collects a patient’s T cells, engineers them in a specialist facility and returns them weeks later. The in vivo...

Cutting Through the Noise: How AI/ML Can Guide Target Selection for Vaccines

Modern vaccine research has entered an era of colossal data abundance. Researchers can now examine complete pathogen genomes and proteomes, measure hundreds of thousands of antigen-specific antibody responses, characterize immune-cell states at single-cell resolution...

Beyond Weight Loss: What Emerging GLP-1 Research Reveals

For many years, the perception of obesity and metabolic syndrome has largely been framed within the context of lifestyle and individual choices. However, an unprecedented paradigm shift is taking place as researchers gain a more profound insight into the physiological...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.